Bunge (BG.US) proposed remedies to gain EU approval for its $8.2bn Viterra acquisition
AInvestFriday, Jul 12, 2024 10:54 am ET
1min read
VTSI --

US grain giant BG (BG.US) has submitted remedies to the EU regulatory authorities in an attempt to get approval for its $8.2bn acquisition of Viterra (Viterra), according to a list on the website of the European Commission.

The details of the remedies were not disclosed.

The European Commission is due to decide by August 1 whether to launch a more detailed investigation into the deal.

“We are confident that the remedies we have made address the concerns of the European Commission, which are limited to specific markets,” a BG spokesman said.

Earlier this week, media reports suggested the deal was unlikely to be completed by the end of August as originally planned, as regulators in Canada, China and the EU have yet to approve the acquisition.

It was reported that BG agreed in June to buy Viterra for $8.2bn in cash and stock, creating a global grain trading giant worth about $34bn including debt, but the deal is likely to face close scrutiny from regulators.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.